Farnam Financial LLC BIO β€” BIO RAD LABS INC

Ownership history in Farnam Financial LLC  Β·  4 quarters on record

AI Ownership Summary

Farnam Financial LLC reported BIO RAD LABS INC (BIO) in 4 quarterly 13F filings from 2025 Q2 through 2026 Q1. Peak portfolio weight reached 2.5% in 2025 Q2. The latest visible filing shows BIO at 0.26% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this BIO ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Farnam Financial LLC's position in BIO RAD LABS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

BIO was reported at 0.26% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
2.5% in 2025 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q2 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

BIO stock page Farnam Financial LLC fund profile Farnam Financial LLC full holdings
How Farnam Financial LLC held BIO β€” position size vs. price
% of Fund (quarterly)    BIO price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
πŸ“‹ Quarterly Holdings History 4 quarters  β–Ύ
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 REDUCED β€” β€” β€” 1,148 -1,190 -50.9% 0.26% $320K 2026-04-28 $279.34
2025 Q4 REDUCED 6.6% -8.0% βœ… 2,338 -165 -6.6% 0.53% $708K 2026-01-26 $299.28
2025 Q3 REDUCED 63.2% +8.3% ❌ 2,503 -4,294 -63.2% 0.55% $702K 2025-10-24 $339.75
2025 Q2 INITIATED β€” β€” β€” 6,797 β€” β€” 2.50% $2.3M 2025-08-13 $287.16

🏒 Other funds also holding BIO

As of 2026 Q1 β€” sorted by position size

Sivik Global Healthcare LLC 3Y 7Y 2.12% Hosking Partners LLP 3Y 7Y 0.69% Marathon Asset Management Ltd 3Y 0.57% C2C Wealth Management, LLC 3Y 0.4% William B. Walkup & Associates, Inc. 0.28% Oak Thistle LLC 3Y 0.25% Boston Trust Walden Corp 3Y 7Y 0.21% Skylands Capital, LLC 3Y 7Y 0.21% EXCHANGE TRADED CONCEPTS, LLC 3Y 0.12% Assenagon Asset Management S.A. 3Y 7Y 0.06%

FAQ About Farnam Financial LLC and BIO

These are the practical questions this page is built to answer before you even open the full history table.

How long has Farnam Financial LLC reported owning BIO?

Farnam Financial LLC reported BIO across 4 quarterly 13F filings, from 2025 Q2 through 2026 Q1.

What was the largest reported BIO position in Farnam Financial LLC's portfolio?

The largest reported portfolio weight for BIO was 2.50% in 2025 Q2.

What is the latest reported BIO position on this page?

The most recent filing on this page is 2026 Q1, when Farnam Financial LLC reported 1,148 shares, equal to 0.26% of portfolio, with an estimated market value of $320K.

What does the chart on this BIO ownership page compare?

The chart compares Farnam Financial LLC's quarterly BIO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Farnam Financial LLC time their BIO position?

Based on 13F filing dates vs. subsequent BIO price moves, Farnam Financial LLC correctly timed 3 out of 3 reported position changes (100%). The annualised alpha on BIO relative to SPY over the holding period was -17.4%.

← Back to Farnam Financial LLC Holdings